Although the administration of prophylactic G-CSF to patients in cohort 2 led to an increase in paclitaxel dose intensity (median intensity 73% vs 57% in cohort 1), the paclitaxel dose was still lower than anticipated and the rate of neutropenia remained high (20%). The gene discussed is CSF3; the disease is neutropenia.